𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients

✍ Scribed by Baert, Filip; Glorieus, Elien; Reenaers, Cathérine; D'Haens, Geert; Peeters, Harald; Franchimont, Dennis; Dewit, Olivier; Caenepeel, Philippe; Louis, Edouard; Van Assche, Gert


Book ID
120584040
Publisher
Oxford University Press
Year
2013
Tongue
English
Weight
446 KB
Volume
7
Category
Article
ISSN
1873-9946

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Predictors of adalimumab dose escalation
✍ Russell D. Cohen; Jeffrey R. Lewis; Hannah Turner; Laura E. Harrell; Stephen B. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB 👁 2 views

Background: Pivotal trials for adalimumab (ADA) demonstrated effectiveness versus placebo for induction and maintenance of remission in moderate to severely active Crohn's disease (CD). Although the approved maintenance regimen in the U.S. is 40 mg subcutaneously every 14 days, some patients require